Maryland Drug Board Advances Ozempic, Other Cost Reviews (1)

Blockbuster diabetes drugs Ozempic and Trulicity will be included in the Maryland prescription drug board’s first cost review, a monthslong process that will help the panel determine whether to set limits on what state health plans pay.

The Maryland Prescription Drug Affordability Board voted Monday to collect data and public comments on the affordability of six of the eight drugs it referred to the state’s stakeholder council in March for further review.

Over the next several months, the board’s staff will review Novo Nordisk A/S‘s Ozempic and Eli Lilly & Co.‘s Type 2 diabetes drug Trulicity, as well ...